(3R,4S,5R,6R)-3,4,5-tris(triMethylsilyloxy)-6-((triMethylsilyloxy)Methyl)tetrahydro-2H-pyran-2-one

1.Overview
Canagliflozin (1) has the chemical name (1S)-1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl] -D-glucitol, jointly developed by Mitsubishi Tanabe Pharma Corporation and Johnson & Johnson. Approved by the U.S. FDA on March 29, 2013, it is the first sodium-glucose cotransporter 2 (SGLT2) inhibitor approved by the FDA. The drug received approval from the European Commission (EC) on November 25, 2013, for the treatment of type 2 diabetes in adults. Dapagliflozin lowers blood glucose levels by inhibiting SGLT2, preventing glucose from being reabsorbed into the bloodstream via the renal tubules and instead excreting it in urine.

2.Applications
2,3,4,6-Tetramethylsilyl-D-glucosyl-1,5-lactone is an antidiabetic agent and an intermediate for dapagliflozin. 2,3,4,6-Tetrakis(O-trimethylsilyl)-D-glucosyl-1,5-lactone serves as a reagent for synthesizing trans-cyclohexane-containing C-glucose and functions as a sodium-glucose cotransporter 2 (SGLT2) inhibitor.

3.Clinical Applications
Dapagliflozin drugs effectively reduce patients’ fasting blood glucose, glycated hemoglobin, and body weight. Their use significantly lowers the risk of hypoglycemia during treatment. Although symptoms such as genital tract infections, polyuria, and frequent urination remain relatively higher compared to the control group, they demonstrate highly pronounced efficacy in lowering blood glucose levels. These drugs hold significant clinical significance and value in the treatment of type 2 diabetes mellitus.